Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis

Yishay Wasserstrum1,2, José M Larrañaga-Moreira3, Cristina Martinez-Veira3

  • 1Leviev Heart Center, Sheba Medical Center in Tel-Ha'Shomer, Ramat-Gan, Israel.

ESC Heart Failure
|April 30, 2022
PubMed

Insights

Hypertrophic cardiomyopathy with reduced ejection fraction (HCMr) affects nearly 3% of patients and is linked to worse outcomes. Identifying predictors like atrial fibrillation and specific genetic variants is crucial for managing this condition.

Area of Science:

  • Cardiology
  • Genetics
  • Heart Failure Research

Background:

  • Hypertrophic cardiomyopathy (HCM) typically presents with preserved ejection fraction.
  • However, a subset of HCM patients develops reduced ventricular function (HCMr), associated with poorer prognosis.
  • Understanding HCMr development and its impact is critical for patient management.

Purpose of the Study:

  • To characterize the phenotype, genetic factors, and clinical events preceding the development of HCMr.
  • To identify predictors for HCMr development in a large HCM cohort.
  • To assess the clinical outcomes associated with HCMr.

Main Methods:

  • A registry of 1328 HCM patients from Spain and Israel was analyzed.
  • Competing-risk analysis identified factors associated with HCMr development.
  • Genetic data were collected, and clinical events preceding HCMr were reviewed.
  • Outcomes, including mortality and need for ventricular assist device (VAD)/heart transplantation, were assessed.

Main Results:

  • HCMr was present at baseline in 2.8% and developed during follow-up in 3.5% of patients.
  • Factors predicting HCMr included younger age at diagnosis, poor functional class, ventricular arrhythmia, atrial fibrillation, pacemaker implantation, and LVEF ≤55%.
  • LV obstruction was associated with a lower risk of HCMr.
  • Genetic testing revealed pathogenic variants in 72% of HCMr patients, most commonly in myosin binding protein C.
  • HCMr was associated with a significantly higher risk of mortality or VAD/heart transplantation.

Conclusions:

  • Reduced ejection fraction in HCM (HCMr) is linked to heart failure and adverse outcomes.
  • Events like arrhythmias and device implantation may precede or result from adverse remodeling in HCMr.
  • Further research is needed to predict and prevent the development of HCMr.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
73
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
48
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
86
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
41
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
78